Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gadospin F is an amphiphilic gadolinium-based contrast agent with high protein-binding affinity specifically formulated for preclinical magnetic resonance imaging (MRI). It is characterized by high relaxivity, leading to increased signal intensity in T1-weighted MRI via shortening of T1 spin-lattice relaxation time. After intravenous injection, it rapidly binds to plasma proteins, extending its vascular residence time and thus prolonging the imaging window. Its affinity enables accumulation in atherosclerotic plaques, supporting direct MRI visualization and quantification of plaque burden in animal models. It is excreted via feces and urine and is used primarily in preclinical (animal) research to study atherosclerosis and vascular pathology. Developed and marketed by Miltenyi Biotec.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gadospin F.